康辰藥業(603590.SH):公司產品蘇靈被繼續納入國家醫保目錄
格隆匯12月29日丨康辰藥業(603590.SH)公佈,根據國家醫療保障局、人力資源和社會保障部2020年12月28日發佈的《關於印發的通知》,公司生產的注射用尖吻蝮蛇血凝酶(商品名“蘇靈”)通過談判續約,被納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2020年)》乙類範圍。
“蘇靈”是目前國內血凝酶製劑市場唯一的國家一類新藥,是“國家863計劃”自主開發項目,是迄今為止我國上市產品中唯一完成全部氨基酸測序的單一組分的蛇毒血凝酶類藥物。“蘇靈”作為手術止血用藥物,被廣泛用於減少手術中的出血,以及控制術後、創傷及疾病引起的出血。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.